Roy Baynes, MD, PhD
Pembrolizumab (Keytruda) did not improve survival as a second-line treatment for PD-L1–positive patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma, according to findings from the phase III KEYNOTE-061 trial.
Among 7 patients with microsatellite instability-high (MSI-H) tumors, the ORR with pembrolizumab was 57.1% and the CR rate was 14.3%. The disease control rate was 71.4%. In those with non–MSI-H tumors (n = 167), the ORR was 9% and the CR rate was 2.4%. The disease control rate was 22.2%.
... to read the full story